M&A
confidence high
sentiment positive
materiality 0.75
Veracyte completes €260M acquisition of HalioDx in cash and stock
VERACYTE, INC.
- Total consideration €260M: ~€147M cash + ~€113M in Veracyte common stock.
- Acquisition of HalioDx, a French immuno-oncology diagnostics company.
- Closing on August 2, 2021, as previously announced June 1 and July 13.
- Stock consideration issued as unregistered securities under Item 3.02.